BACKGROUND: Growing evidence suggests that the tumor immune microenvironment influences breast cancer development and prognosis. Density of tumor-infiltrating lymphocytes (TILs) within invasive breast cancer is correlated with response to therapy, especially in triple-negative disease. The clinical relevance and outcomes of TILs within ductal carcinoma in situ (DCIS) are less understood. METHODS: Our institutional database of 668 patients with pure DCIS from 2010 to 2018 was queried. TILs were evaluated by International TILs Working Group guidelines. Percentage of TILs was assessed from the densest focus (hotspot) in one high-power field of stroma touching the basement membrane. Statistical methods included cluster analyses (to define sparse versus dense TILs), logistic, and Cox regression models. RESULTS: Sixty-nine patients with DCIS and TILs were evaluated, of whom 54 (78%) were treated by breast-conserving surgery. Thirteen (19%) patients had ipsilateral recurrence. Each recurrence (n = 13) was matched to four controls (n = 56) based on date of surgery. Median follow-up was 6.7 years. TILs were defined as sparse (< 45%) or dense (≥ 45%). Dense TILs were associated with younger age (p = 0.045), larger tumor size (p < 0.001), high nuclear grade (p = 0.010), comedo histology (p = 0.033), necrosis (p = 0.027), estrogen receptor (ER) negativity (p = 0.037), and ipsilateral recurrence (p = 0.001). Nine patients with dense TILs had mean time to recurrence of 73.5 months compared with four patients with sparse TILs with mean time to recurrence of 97.9 months (p = 0.003). CONCLUSIONS: Dense TILs were significantly associated with age, tumor size, nuclear grade, comedo histology, necrosis, and ER status and was a significant predictor of recurrence in patients with pure DCIS.
BACKGROUND: Growing evidence suggests that the tumor immune microenvironment influences breast cancer development and prognosis. Density of tumor-infiltrating lymphocytes (TILs) within invasive breast cancer is correlated with response to therapy, especially in triple-negative disease. The clinical relevance and outcomes of TILs within ductal carcinoma in situ (DCIS) are less understood. METHODS: Our institutional database of 668 patients with pure DCIS from 2010 to 2018 was queried. TILs were evaluated by International TILs Working Group guidelines. Percentage of TILs was assessed from the densest focus (hotspot) in one high-power field of stroma touching the basement membrane. Statistical methods included cluster analyses (to define sparse versus dense TILs), logistic, and Cox regression models. RESULTS: Sixty-nine patients with DCIS and TILs were evaluated, of whom 54 (78%) were treated by breast-conserving surgery. Thirteen (19%) patients had ipsilateral recurrence. Each recurrence (n = 13) was matched to four controls (n = 56) based on date of surgery. Median follow-up was 6.7 years. TILs were defined as sparse (< 45%) or dense (≥ 45%). Dense TILs were associated with younger age (p = 0.045), larger tumor size (p < 0.001), high nuclear grade (p = 0.010), comedo histology (p = 0.033), necrosis (p = 0.027), estrogen receptor (ER) negativity (p = 0.037), and ipsilateral recurrence (p = 0.001). Nine patients with dense TILs had mean time to recurrence of 73.5 months compared with four patients with sparse TILs with mean time to recurrence of 97.9 months (p = 0.003). CONCLUSIONS: Dense TILs were significantly associated with age, tumor size, nuclear grade, comedo histology, necrosis, and ER status and was a significant predictor of recurrence in patients with pure DCIS.
Authors: Anna K Casasent; Mathilde M Almekinders; Charlotta Mulder; Proteeti Bhattacharjee; Deborah Collyar; Alastair M Thompson; Jos Jonkers; Esther H Lips; Jacco van Rheenen; E Shelley Hwang; Serena Nik-Zainal; Nicholas E Navin; Jelle Wesseling Journal: Nat Rev Cancer Date: 2022-10-19 Impact factor: 69.800
Authors: Julia Solek; Jedrzej Chrzanowski; Adrianna Cieslak; Aleksandra Zielinska; Dominika Piasecka; Marcin Braun; Rafal Sadej; Hanna M Romanska Journal: Biomedicines Date: 2022-05-03
Authors: Alexa C Glencer; Jasmine M Wong; Nola M Hylton; Gregor Krings; Emma McCune; Harriet T Rothschild; Tristan A Loveday; Michael D Alvarado; Laura J Esserman; Michael J Campbell Journal: NPJ Breast Cancer Date: 2021-05-25
Authors: Farbod Darvishian; Yinxiang Wu; Ugur Ozerdem; Jennifer Chun; Sylvia Adams; Amber Guth; Deborah Axelrod; Richard Shapiro; Andrea B Troxel; Freya Schnabel; Daniel Roses Journal: Breast Date: 2022-04-22 Impact factor: 4.254
Authors: Mathilde M Almekinders; Tycho Bismeijer; Tapsi Kumar; Fei Yang; Bram Thijssen; Rianne van der Linden; Charlotte van Rooijen; Shiva Vonk; Baohua Sun; Edwin R Parra Cuentas; Ignacio I Wistuba; Savitri Krishnamurthy; Lindy L Visser; Iris M Seignette; Ingrid Hofland; Joyce Sanders; Annegien Broeks; Jason K Love; Brian Menegaz; Lodewyk Wessels; Alastair M Thompson; Karin E de Visser; Erik Hooijberg; Esther Lips; Andrew Futreal; Jelle Wesseling Journal: Br J Cancer Date: 2022-06-29 Impact factor: 9.075
Authors: Lujain Alsaleh; Chen Li; Justin L Couetil; Ze Ye; Kun Huang; Jie Zhang; Chao Chen; Travis S Johnson Journal: Cancers (Basel) Date: 2022-10-04 Impact factor: 6.575